Drug major Jubilant Life Sciences has received a nod from the US Food and Drugs Administration (FDA) to market a generic diuretic medicine, the company said on Friday.
The Spironolactone tablets (25 mg, 50 mg and 100 mg), which received the abbreviated new drug application approval, is the generic version of GD Searle’s Aldactone. It is used to treat fluid retention in the body caused by conditions such as congestive heart failure and cirrhosis of the liver.
Jubilant said it will launch this product, which has a market size of $87 million a year, in the first quarter of the fiscal year 2015-16.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.